Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 221

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview 8
Therapeutics Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area 10
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication 11
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies 18
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes 34
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment 36
Assessment by Monotherapy/Combination Products 36
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development 43
Aduro BioTech, Inc. 43
Agenus, Inc. 44
Aurigene Discovery Technologies Limited 45
BeiGene, Ltd. 46
Beijing Hanmi Pharmaceutical Co., Ltd. 47
BIOCAD 48
Cellular Biomedicine Group, Inc. 49
CytomX Therapeutics, Inc. 50
Eli Lilly and Company 51
Enumeral Biomedical Holdings, Inc. 52
Immunovo BV 53
Jiangsu Hengrui Medicine Co., Ltd. 54
Jounce Therapeutics, Inc. 55
Les Laboratoires Servier SAS 56
MacroGenics, Inc. 57
MD Biosciences GmbH 58
MedImmune, LLC 59
Merck & Co., Inc. 60
Molecular Partners AG 62
Novartis AG 63
Ono Pharmaceutical Co., Ltd. 64
Pfizer Inc. 68
PharmaEssentia Corporation 69
Pieris Pharmaceuticals Inc 70
Regeneron Pharmaceuticals Inc 71
Sutro Biopharma, Inc. 72
Symphogen A/S 73
Tasly Pharmaceutical Group Co., Ltd. 74
Tesaro, Inc. 75
Theravectys SA 76
Tikcro Technologies, Ltd. 77
Vyriad 78
Xencor, Inc. 79
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles 80
AM-0001 - Drug Profile 80
AMP-224 - Drug Profile 81
Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile 83
AUR-012 - Drug Profile 84
BGB-108 - Drug Profile 85
BGBA-317 - Drug Profile 86
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 87
Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile 88
durvalumab + MEDI-0680 - Drug Profile 89
ENUM-003 - Drug Profile 90
ENUM-388D4 - Drug Profile 92
GXP-2 - Drug Profile 93
IBI-308 - Drug Profile 94
JS-001 - Drug Profile 95
MD-402 - Drug Profile 96
mDX-400 - Drug Profile 97
MEDI-0680 - Drug Profile 98
MGD-013 - Drug Profile 99
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 100
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 101
Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 102
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 103
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 104
Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile 105
Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile 106
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 107
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 108
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 109
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 110
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 111
Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 112
Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile 113
Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile 114
Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile 115
Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile 116
Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile 117
nivolumab - Drug Profile 118
Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile 148
pazopanib hydrochloride + pembrolizumab - Drug Profile 149
PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile 150
PDR-001 - Drug Profile 151
PEGMP-7 - Drug Profile 152
pembrolizumab - Drug Profile 153
PF-06801591 - Drug Profile 185
PRS-332 - Drug Profile 186
Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile 187
REGN-2810 - Drug Profile 188
SHR-1210 - Drug Profile 190
SNPD-07 - Drug Profile 191
STIA-1110 - Drug Profile 192
TSR-042 - Drug Profile 193
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 194
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 195
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 196
XmAb-20717 - Drug Profile 197
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects 198
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products 199
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases 200
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 216
Disclaimer 217

List of Tables

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Comparative Analysis by Unknown Stage Development, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Development by Companies, H2 2016 (Contd..4) 28
Products under Development by Companies, H2 2016 (Contd..5) 29
Products under Development by Companies, H2 2016 (Contd..6) 30
Products under Development by Companies, H2 2016 (Contd..7) 31
Products under Development by Companies, H2 2016 (Contd..8) 32
Products under Development by Companies, H2 2016 (Contd..9) 33
Products under Development by Companies, H2 2016 (Contd..10) 34
Products under Development by Companies, H2 2016 (Contd..11) 35
Products under Development by Companies, H2 2016 (Contd..12) 36
Products under Development by Companies, H2 2016 (Contd..13) 37
Number of Products under Investigation by Universities/Institutes, H2 2016 38
Products under Investigation by Universities/Institutes, H2 2016 39
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Pipeline by Aduro BioTech, Inc., H2 2016 47
Pipeline by Agenus, Inc., H2 2016 48
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 49
Pipeline by BeiGene, Ltd., H2 2016 50
Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 51
Pipeline by BIOCAD, H2 2016 52
Pipeline by Cellular Biomedicine Group, Inc., H2 2016 53
Pipeline by CytomX Therapeutics, Inc., H2 2016 54
Pipeline by Eli Lilly and Company, H2 2016 55
Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 56
Pipeline by Immunovo BV, H2 2016 57
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 58
Pipeline by Jounce Therapeutics, Inc., H2 2016 59
Pipeline by Les Laboratoires Servier SAS, H2 2016 60
Pipeline by MacroGenics, Inc., H2 2016 61
Pipeline by MD Biosciences GmbH, H2 2016 62
Pipeline by MedImmune, LLC, H2 2016 63
Pipeline by Merck & Co., Inc., H2 2016 64
Pipeline by Molecular Partners AG, H2 2016 66
Pipeline by Novartis AG, H2 2016 67
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 68
Pipeline by Pfizer Inc., H2 2016 72
Pipeline by PharmaEssentia Corporation, H2 2016 73
Pipeline by Pieris Pharmaceuticals Inc, H2 2016 74
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 75
Pipeline by Sutro Biopharma, Inc., H2 2016 76
Pipeline by Symphogen A/S, H2 2016 77
Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 78
Pipeline by Tesaro, Inc., H2 2016 79
Pipeline by Theravectys SA, H2 2016 80
Pipeline by Tikcro Technologies, Ltd., H2 2016 81
Pipeline by Vyriad, H2 2016 82
Pipeline by Xencor, Inc., H2 2016 83
Dormant Projects, H2 2016 202
Discontinued Products, H2 2016 203

List of Figures

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Mechanism of Actions, H2 2016 41
Number of Products by Stage and Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 45
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Humanized Mouse Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious diseases) & End User(Pharmaceutical & Biotech Companies, CRO)) - Global Forecast to 2021
    Published: 23-Jan-2017        Price: US 5650 Onwards        Pages: 182
    The humanized mouse model market is projected to reach USD 116.0 million by 2021 from USD 73.3 million in 2016, growing at a CAGR of 9.6% in the next five years (2016 to 2021). Growing adoption of personalized medicine to fuel the demand for personalized mice models, continuous support in the form of investments and grants from the government and private sectors, and increase in R&D activities carried out by pharmaceutical and biotechnology companies are the key factors driving th......
  • Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021
    Published: 19-Jan-2017        Price: US 5650 Onwards        Pages: 178
    The top 10 cellular analysis market is expected to reach USD 41.34 billion by 2021 from USD 28.66 billion in 2016, at a CAGR of 7.6% during the forecast period. Factors such as increasing government support in the form of funding in cell biology-based research, growing biotechnology industry, increasing prevalence of chronic and infectious diseases, and rising number of cancer cases are driving the growth of the top 10 cellular analysis market. The top 10 cellular analysis market is c......
  • Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021
    Published: 13-Jan-2017        Price: US 5650 Onwards        Pages: 209
    The global transfection reagents and equipment market is expected to reach USD 1.02 billion by 2021 from USD 715.4 million in 2016, at a CAGR of 7.5% during the forecast period 2016 to 2021. Over the years, the transfection reagents and equipment market has witnessed various technological advancements in equipment as well as reagents to address the requirements of researchers and biotechnology & biopharmaceutical companies. These advancements have led to the development of transfe......
  • Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021
    Published: 12-Jan-2017        Price: US 5650 Onwards        Pages: 253
    The rat model market is projected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, growing at a CAGR of 8.7% during the forecast period.Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.......
  • Global Mycoplasma Testing Market Research Report 2017
    Published: 10-Jan-2017        Price: US 2999 Onwards        Pages: 116
    This report studies Mycoplasma Testing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Abbott Affymetrix Beckman Coulter/Danaher Becton Dickinson BioMerieux Bio-Rad Cepheid Diamedix/Erba DiaSorin Eiken Chemical Elitech Group Enzo B......
  • Sphingosine 1-Phosphate (S1P) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate (S1P) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate (S1P) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other d......
  • Inositol 5'-Phosphatase (SHIP) Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Inositol 5'-Phosphatase (SHIP) Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Inositol 5'-Phosphatase (SHIP) Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including te......
  • Insulin Like Growth Factor 1 (IGF-1) Activators -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Insulin Like Growth Factor 1 (IGF-1) Activators-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Insulin Like Growth Factor 1 (IGF-1) Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs